Oct 26 (Reuters) - West Pharmaceutical Services Inc :West announces third-quarter 2017 results.Sees fy 2017 adjusted earnings per share $2.74 to $2.79.Q3 earnings per share $0.67.Q3 sales $398.2 million versus I/B/E/S view $385.9 million.Q3 earnings per share view $0.53 -- Thomson Reuters I/B/E/S.Sees FY 2017 sales $1.595 billion to $1.605 billion.Says hurricanes in Puerto Rico had a negative impact on third-quarter 2017 sales of approximately $2 million.West Pharmaceutical Services Inc says reaffirmed long-term financial targets.West Pharmaceutical Services Inc - company estimates its 2017 capital spending to be approximately $150 million.West Pharmaceutical Services Inc - expects 2018 constant-currency, organic sales growth to be in range of 6% to 8%.FY2017 earnings per share view $2.67, revenue view $1.59 billion -- Thomson Reuters I/B/E/S.FY2018 revenue view $1.72 billion -- Thomson Reuters I/B/E/S.West Pharmaceutical - at current low levels operations at Puerto Rico , estimate Q4 2017 sales to be adversely impacted by approximately $5 million.
West Pharmaceutical Services Inc Says Raising Our Full : Year 2016 organic sales growth guidance to a new range of between 7% and 9% . West announces second quarter 2016 results . Sees fy 2016 adjusted earnings per share $2.15 to $2.25 . Q2 adjusted earnings per share $0.59 excluding items . Q2 earnings per share $0.60 . Q2 sales $388 million versus i/b/e/s view $384.6 million . Sees fy 2016 sales $1.505 billion to $1.52 billion . Q2 earnings per share view $0.56 -- Thomson Reuters I/B/E/S . Fy2016 earnings per share view $2.21, revenue view $1.50 billion -- Thomson Reuters I/B/E/S .West pharmaceutical services inc says company estimates its 2016 capital spending at between $150 million and $175 million.